Photo by jeremybishop from unsplash
Advanced thymic epithelial tumors (TETs) are indolent and poorly responsive to chemotherapy. PD‐1/PD‐L1 inhibitors have shown remarkable clinical benefit in several cancers; however, many immunomodulatory molecules have been identified that… Click to show full abstract
Advanced thymic epithelial tumors (TETs) are indolent and poorly responsive to chemotherapy. PD‐1/PD‐L1 inhibitors have shown remarkable clinical benefit in several cancers; however, many immunomodulatory molecules have been identified that affect the immune response. This study examined the progonostic roles of PD‐L1, transforming growth factor‐β (TGF‐β), and CD8+ tumor‐infiltrating lymphocytes (CD8+ TILs) in patients with TETs.
Keywords:
transforming growth;
advanced thymic;
growth factor;
tumor infiltrating;
thymic epithelial;
epithelial tumors
Journal Title: Thoracic Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Thoracic Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!